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Abstract: Pathological accumulation of misfolded α-synuclein (α-syn) in the brain 
plays a key role in the pathogenesis of Parkinson’s disease, leading to neuronal 
dysfunction and motor disorders. The underlying mechanisms linking α-syn 
aggregations with neurotransmitter disturbance in Parkinson’s brains are not well 
characterized. In the present study, we investigated transgenic mice expressing an 
aggregation-prone form of full-length human α-syn (h-α-synL62) linked to a signal 
sequence. These mice display dopamine depletion and progressive motor deficits. 
We detected accumulation of α-syn in cholinergic interneurons where they are 
colocalized with choline acetyltransferase. Using microdialysis, we measured 
acetylcholine levels in the striatum at baseline and during stimulation in the open field 
and with scopolamine. While no difference between wild-type and transgenic mice 
was detected in 3 month old mice, striatal acetylcholine levels at 9 months of age 
were significantly higher in transgenic mice. Concomitantly, high-affinity choline 
uptake was also increased while choline acetyltransferase and acetylcholine esterase 
activities were unchanged. The results suggest a disinhibition of acetylcholine 
release in α-syn transgenic mice.  
Keywords: alpha-synuclein, acetylcholine, microdialysis, cholinergic interneurons, 
scopolamine, muscarinic receptors 
Introduction 
Parkinson`s disease (PD) is a common neurodegenerative disorder in humans with 
typical motor symptoms such as bradykinesia, rigidity and tremor. The 
pathophysiological process in the brain is characterized by a high load of the protein 
α-syn, which gradually deposits to form intracellular aggregates and fibrils known as 
Lewy bodies and Lewy neurites.1  
The physiological function of α-syn is not fully understood, but there is clear evidence 
for it playing a role in vesicular function at the synaptic terminal.2 Monomeric α-syn 
interacts with soluble N-ethylmaleimide-sensitive factor attachment protein receptor 
(SNARE) complexes, which are directly involved in vesicle fusion and exocytosis.3 
Therefore, a change in the structure, due to oligomerization and aggregation, can 
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contribute to degenerative processes and altered synaptic function. Misfolded α-syn 
is known to impair axonal transport,4 and increase neuroinflammation.5 
It is proposed that motor symptoms in PD are caused by a progressive loss of 
dopamine (DA) neurons projecting from the midbrain to the striatum and therefore 
influence basal ganglia function.6 However, DA interacts with a variety of other 
neurotransmitters to control motor behavior. It is well known that the balance 
between acetylcholine (ACh) and DA in the striatum is necessary for normal motor 
function. The striatum is composed mainly of GABAergic projection neurons (medium 
spiny neurons, MSNs) and interneurons.7 Striatal cholinergic interneurons (ChIs) 
represent only about 2% of the total striatal neuronal population,8 but have large 
arborizing axonal varicosities within the striatum. This suggests that these neurons 
may have an important role in modulating striatal activity.9 ChIs receive inputs from 
cortical and thalamic glutamatergic neurons and from dopaminergic projections from 
the Substantia Nigra pars Compacta (SNpC).10 Release of ACh from ChIs is 
regulated by both dopaminergic receptors (D1/D5 and D2) and muscarinic ACh 
receptors (M2/M4) on somatodendritic and axonal sites.11 D2 receptors inhibit striatal 
ACh efflux by lowering both synaptic activation and autonomous action potential 
firing. D1 receptors are located mainly at the somatodendritic sites where they 
depolarize the cell and enhance ACh release. The muscarinic M2/M4 receptors both 
reduce ACh release by either reducing exocytosis on the axonal site or inducing 
hyperpolarization on the somatodendritic site. DA depletion in the striatum can 
therefore lead to a disturbed function of ChIs, contributing to the emergence of motor 
symptoms. 
Several genetic mouse models of PD have been developed that reflect many aspects 
of the disease and the underlying mechanisms of α-syn pathology contributing to 
motor symptoms and neurodegeneration.12 Most of the transgenic synuclein models 
overexpress human wild-type α-syn or α-syn carrying A53T or A30P mutations.12 
Overexpression of α-syn has been shown to reduce dopamine release in transgenic 
mice.13 However, not all a-syn-overexpressing transgenic mice form intracellular 
inclusions or cell loss in the substantia nigra.14 The vulnerability of dopamine neurons 
to α-syn overexpression has been well studied, but several reports have shown that 
noradrenergic, serotonergic or cholinergic neurotransmitter systems are also 
affected.15  
We have recently reported on transgenic h-α-synL62 (L62) mice, which show high 
levels of expression of human α-syn (h-α-syn); aggregates were already observed by 
3 months of age.16 L62 showed a hypoactive phenotype and age progression was 
associated with more severe impairments in motor activity and coordination. In 
microdialysis experiments, a progressive lowering of amphetamine-induced 
dopamine (DA) release in the striatum appeared in L62 between 3 and 9 months of 
age.16 In the present study, we used h-α-synL62 mice at the age of 3 and 9 months 
to investigate the impact of h-α-syn aggregation on cholinergic functions in the 
striatum.  
Results and Discussion 
Cholinergic neurons are affected by h-α-syn inclusions. The pathologic hallmark 
of PD is a degeneration of dopaminergic neurons of the Substantia nigra pars 
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compacta and of their striatal terminals. However, there are also reports of neuronal 
loss and alterations in cholinergic neurotransmission in the basal forebrain and in 
cortical structures.17,18 Cholinergic neurons are characterized by expression of the 
enzyme choline acetyltransferase (ChAT), which is localized to the soma and 
presynaptic endings. Alpha-synuclein plays a major role in the presynaptic 
cytoskeleton and accumulates specifically in presynaptic terminals. In histological 
staining experiments from L62, h-α-syn inclusions are pronounced in ChAT-positive 
neurons in several brain areas including striatum, olfactory nucleus, spinal cord and 
nucleus basalis magnocellularis (Fig. 1A) that are all known for their role in PD 
pathology. Cell counts of ChAT-positive neurons in the striatum confirmed a 
significant reduction of cells in L62 mice at 3 and 8 months of age relative to WT (Fig. 
1B). Our results suggest that accumulation of h-α-syn in cholinergic neurons causes 
a loss of ChIs in the striatum, a brain region particularly important for the control of 
movements. These findings could be confirmed in another study with a model of 
widespread progressive synucleinopathy throuought the forebrain. Animals displayed 
progressive reduction in cortical and striatal ChAT positive interneurons, indicating 
that cholinergic interneurons may be more vulnerable to h-α-syn toxicity.19 However, 
in our model there is a lack of progression in the loss of ChAT positive neurons 
between 3 and 9 months of age. In L62 mice, h-α-syn aggregates reached their 
maximum aggregation state also with 3 months and showed no age progression in 
aggregation, but in severity of motor symptoms.16 Possibly there are other 
mechanisms, such as changes in neurotransmission, which contribute to the 
progression of motor symptoms. 
 
Figure 1: Cholinergic neurons are affected by h-α-syn inclusions in L62 mice. (A) A 
subset of cholinergic neurons, positive for ChAT (red), in the striatum, the olfactory 
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nucleus, the nucleus basalis magnocellularis and the spinal cord were also stained 
for h-α-syn (green) inclusions in L62 mice. The yellow color in the merged images 
indicates colocalization of ChAT and h-α-syn. Scale bars: 20 µm. (B) Manual cell 
counting of striatal interneurons at Bregma 0.74 ± 0.25 revealed loss of striatal 
cholinergic interneurons in transgenic L62 compared to WT mice at 3 and 8 months 
of age. Values are given as mean ± SEM (N = 8-12 mice per group). Statistics: two-
way ANOVA for genotype and age as variables: Genotype p < 0.0001, age and 
interaction ns. Bonferroni posttest: **, p < 0.01 vs WT. 
High-affinity choline uptake is upregulated in 9 months old transgenic mice. To 
gain a better understanding of the overall effects of h-α-syn on cholinergic synapses, 
the activity of three enzymes and transporters obligatory for ACh synthesis was 
measured (Fig. 2 A–C). ChAT is localized in presynaptic terminals and is responsible 
for the synthesis of ACh. When ChAT activities were determined, we found an age-
dependent increase in ChAT activity (p<0.01), but no genotype effect (Fig. 2A). 
Hence, ChAT activity was unchanged in spite of reduced cholinergic cell counts (Fig. 
1B). However, ChAT activity is not limiting for ACh synthesis.  
The activity of high-affinity choline uptake (HACU) reflects the transport of choline 
(Ch) back into the presynaptic compartment and is considered a rate-limiting step for 
the synthesis of ACh.20 HACU activity is controlled by the presence of the choline 
transporter-1 (CHT-1) in the plasma membrane which is internalized depending on 
the neuronal firing rate.21 Hence, HACU measured ex vivo provides a measure of in 
vivo turnover of ACh prior to sacrifice.22 The activity of HACU in 9 month old mice 
was significantly greater for L62 mice relative to WT (Fig. 2B, p=0.02). This suggests 
that degeneration of cholinergic cells in the striatum can lead to compensatory up-
regulation of HACU activity which maintains cholinergic function. This finding is 
reminiscent of a study with mice, which were heterozygous for a null mutation in the 
ChAT gene. In these mice, ChAT activity was reduced by 50%, but brain ACh levels 
were normal due to an increased expression of CHT1.23  
Ex vivo-data of the activity of the acetylcholinesterase (AChE) reflect the rate of 
breakdown of ACh in the synaptic cleft because AChE terminates the action of ACh. 
There was no difference in AChE activity between the two mouse strains at 9 months 
of age (Fig. 2C). Hence, the rate of breakdown of ACh is not affected by h-α-syn. 
Figure 2. Activity of ChAT (A) in 3 and 9 month old mice, HACU (B) and AChE (C) in 
9 month old mice. Data were obtained in hemibrain homogenates. Values are given 
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as mean ± SEM (N = 6-10 mice per group). Statistics: two-way ANOVA for genotype 
and age as variables: (A) Age F1,36=7.5, p < 0.01, genotype and interaction ns. (B) 
Student’s t-test, two-tailed: p=0.02; (C) p=0.48.  
9 month old L62 mice display increased striatal ACh release during the open 
field experiment. To confirm a possible cholinergic phenotype caused by h-α-syn 
accumulation, microdialysis measurements of the neurotransmitter ACh were 
performed. The striatum was chosen as region of interest, since previous 
experiments in L62 mice revealed that striatal dopamine levels are reduced in 9 
month old mice upon amphetamine challenge (2 mg/kg). Baseline levels of DA in the 
striatum of 9 month old WT and L62 mice were about 1 nM and during amphetamine 
stimulation they increased 400% from baseline in WT and 250% from baseline in L62 
mice.16 This difference in DA release was significant and shows that, despite of lack 
of neuronal loss in the substantia nigra, striatal DA neurons are impaired in 
transgenic L62 mice. As mentioned above, ChIs densely innervate the entire striatal 
complex and receive input from extrinsic DA neurons of the mesencephalic 
tegmentum.19 The output targets of the ChIs are the MSNs, which are important for 
initiating and controlling movements.  
Extracellular baseline concentrations of ACh were slightly higher in L62 but not 
significantly different to WT at 3 and 9 months of age at the beginning of day 1 
dialysis (Fig. 3A). The findings of baseline levels of ACh in the striatum are in 
accordance with concentrations stated in the literature, which are about 1-5 nM.24,25 
In comparison to ACh, choline, the precursor of ACh, was lower in 9 month old mice, 
an effect that was significant in L62 mice (Fig. 3B). This is possibly caused by an 
increased turnover of ACh and heightened HACU activity of L62 mice at 9 months of 
age (Fig. 2B), resulting in an increased uptake of extracellular choline into the 
presynapse. It should be noted, however, that choline levels are much higher than 
ACh levels, and choline metabolism mostly reflects phospholipid metabolism and not 
ACh release.20  
When mice were placed into a novel environment (open field), ACh release was 
stimulated by approx. 2-fold (Figs. 3C, D). This increase of ACh in the dorsal striatum 
is probably due to motor activity during exploration in the open field.26 There are no 
data for open-field induced increases of ACh in the striatum of mice in the literature. 
However, in experiments with Wistar rats, increased motor activity during the dark 
phase of the rats' day-night cycle led to an increase in striatal ACh of 58%.27 
The time course in 3 month old mice was identical between L62 and WT (Fig. 3C). In 
9 month old (Fig. 3D) mice, however, the movement stimulated rise in ACh was 
higher in L62 mice during exploration and remained elevated over a longer period 
after placing mice back into the home cage (two-way ANOVA: Genotype F1, 22=7.32, 
p=0.01). In similar experiments, Frahm et al. monitored the distance moved in an 
open field, in which L62 mice showed a reduced activity16, but this was not recorded 
here. Both reduced locomotor activity and elevated ACh levels can be explained by 
an impaired regulation of firing of ChIs. Striatal cholinergic interneurons express both 
D1 and D2 DA receptors.28,29 Dopamine modulates striatal cholinergic tone via both 
excitatory and inhibitory actions. D2 receptor stimulation slows the discharge rate of 
striatal ChIs by modulating sodium ion currents,30 and inhibits striatal ACh release.31 
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Conversely, D1 receptor stimulation facilitates ACh release.32 Therefore, impairment 
in dopaminergic D2 receptor regulation of ChIs would explain an increased ACh 
release after stimulation.  
Figure 3. Baseline ACh and Ch levels before stimulation (A and B). Statistics: two-
way ANOVA for genotype and age as variables: (A) Genotype, age and interaction 
ns. (B) Age F1, 53=5.6, p=0.02, genotype and interaction ns. Bonferroni post-test: *, 
p<0.05 vs L62. Extracellular striatal ACh levels in 3 and 9 month old mice before, 
during and after exposure to the open field (C and D). Statistics: two-way ANOVA for 
genotype and time as variables: (C) Time F23, 690=20.47, p<0.0001, genotype and 
interaction ns. (D) Time F23, 506=22.35, p<0.0001, genotype F1, 22=7.32, p=0.01, 
interaction F23, 506= 2.25, p=0.0008. Bonferroni post-test: *, p<0.05; **, p<0.01; ***, 
p<0.001 for L62 9m vs WT 9m. Values are presented as mean ± SEM, derived from 
absolute values, not corrected for in vitro recovery (N=12-18 mice per group). Data 
for (A) and (B) were obtained for individual animals and averaged from 5-6 baseline 
samples for each mouse. 
9 month old L62 mice display increased striatal ACh release during infusion of 
scopolamine. Besides DA receptors, muscarinic AChRs modulate the release of 
ACh in the striatum. ChIs express M2 and M4 receptors, which are present on the 
somatodendritic areas and the axon terminals.33 At the somatodendritic site, mAChR 
are proposed to inhibit striatal ChIs by inducing hyperpolarization mediated by an 
outward K+ current. mAChRs on the axon terminals cause presynaptic autoinhibition 
of ACh release by modulating K+ and Ca2+ channels.34 Scopolamine acts as a 
muscarinic antagonist; it blocks inhibitory M2/M4 receptors and causes an increase 
of extracellular ACh.35 In 3 month old mice, scopolamine led to a 3-fold increase of 
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ACh in both lines (Fig 4C). In 9 month old mice (Fig. 4D), however, L62 mice 
displayed much higher increases in extracellular ACh levels than wild-type mice 
(p<0.01). Most likely, the amplified effect of scopolamine in L62 mice can be 
explained by a disinhibition of ChIs in the striatum due to DA depletion and loss of 
inhibition by D2 receptors. Furthermore, DA denervation has been shown previously 
to reduce M4 mRNA which resulted in a loss of negative feedback inhibition and 
increased ACh release and turnover.36 This mechanism may explain the small but 
significant increase of basal ACh in L62 vs. wild-type mice before scopolamine 
infusion (Fig. 4A). This increase in baseline levels of ACh is also reflected in the 
increased HACU activity measured in 9 month old mice (Fig. 2B).  
Figure 4. Baseline ACh and Ch levels before stimulation (A and B). Statistics: two-
way ANOVA for genotype and age as variables: (A) Genotype F1, 54 = 3.06, p = 0.09, 
age F1, 54 = 3.5, p = 0.07, interaction ns. Bonferroni post-test: *, p < 0.05 vs L62. (B) 
Genotype, age and interaction ns. Extracellular striatal ACh levels in 3 and 9 month 
old mice before, during and after scopolamine exposure (shaded area) (C and D). 
Statistics: two-way ANOVA for genotype and time as variables: (C) Genotype, time 
and interaction ns. (D) Genotype F1, 24 = 8.69, p = 0.007, time F23, 552 = 36.13, p < 
0.0001, interaction F23, 552 = 3.19, p < 0.0001. Bonferroni post-test: *, p < 0.05; **, p < 
0.01; ***, p < 0.001 for L62 9m vs WT 9m. Values are presented as mean ± SEM, 
derived from absolute values, not corrected for in vitro recovery (N = 12-18 mice per 
group). Data for (A) and (B) were obtained from individual animals and averaged 
from 5-6 baseline samples for each mouse. 
Collectively, our results show that L62 at 9 months of age display higher striatal ACh 
release from challenged ChIs. The difference in extracellular ACh release seems to 
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be independent of the impact of α-syn on ChAT neurons in the striatum. Although 
there is a reduction in ChAT positive cells in L62 mice, the cell counts did not decline 
with age. Furthermore, there was no change in the activity of ChAT. There is 
evidence that both phosphorylation and dephosphorylation of ChAT can alter its 
catalytic activity and thereby regulate ACh synthesis.37 α-syn may also have a 
chaperone-like function and transgenic overexpression of this protein can lead to 
changes in phosphorylation of ChAT.38 However, it is generally considered, that the 
activity of the high affinity choline transporter (HACU) is the rate-limiting step in ACh 
synthesis and release, and measurements confirmed an increased activity of HACU 
in L62 mice.  
We suggest that the impairment of dopamine neurons leads to a disturbance in the 
normal DA-ACh balance and that the increased cholinergic activity in this model may 
arise from the reduced inhibition of dopaminergic neurons ending upon cholinergic 
cells in the dorsal striatum.39 The plastic alterations of striatal cholinergic 
interneurons by DA denervation have never been investigated in α-syn 
overexpressing mouse models. A change in activity of ChIs might have 
consequences on movement and contribute to the progression of motor symptoms in 
PD. 
Glucose and lactate levels increase in the open field but not during 
scopolamine challenge. Brains of PD patients showed glucose hypometabolism,40 
and α-syn aggregation in transgenic mouse models led to mitochondrial 
dysfunction.41 We investigated the influence of α-syn aggregation on brain energy 
metabolism by measuring extracellular glucose and lactate levels in microdialysate of 
L62 and WT mice. Results were obtained from 3-4 consecutive baseline samples, 
and 3-4 consecutive samples after placing mice into the open field and stimulating 
with scopolamine, respectively.  
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Figure 5: Glucose levels on day 1 (A) and day 2 (B) and lactate levels on day 1 (C) 
and day 2 (D) in 9 month old mice before and after stimulation measured in 
microdialysates. Statistics: two-way ANOVA for genotype and challenge as variables: 
(A) Genotype F1,40= 4.7, p=0.04, challenge F1,40=18.    15, p=0.0001, interaction ns. 
Bonferroni post-test: **, p<0.01 vs WT, *, p<0.05 vs L62. (B) Genotype, challenge 
and interaction ns. (C) Challenge F1,28=14.03, p=0.0008, genotype and interaction ns. 
Bonferroni post-test: *, p<0.05 vs L62. (D) Genotype, challenge and interaction ns. 
Values are presented as means ± SEM. Data were obtained from individual animals 
and averaged from 3-4 consecutive samples. (A/C) N=9-11, (B/D) N=8-9 mice per 
group. 
Glucose is the standard fuel for brain energy production and a precursor of ACh 
synthesis. It is taken into cholinergic presynaptic terminals and transformed into 
acetyl-Coenzyme A, which is used subsequently to synthesize ACh. ACh levels 
depend on glucose oxidation in periods of increased cholinergic activity.42 
Extracellular glucose levels reflect a balance between supply from the blood and 
uptake into neurons. Behavioral stimulation in the open field caused glucose levels to 
increase, likely indicating an increased flux of glucose from blood during motor 
activity (Fig. 5A). Blood glucose, blood flow, and glucose uptake in the brain are 
coupled,43 and thus an increase of glucose can reflect an increase of blood sugar or 
of blood flow in the striatum. Glucose levels were slightly greater in L62 at baseline 
(Fig. 5A), but the extent of glucose mobilization in the open field was almost identical 
in WT and L62 mice indicating that h-α-syn does not cause a generised impairment 
in the ability of the brain to respond adequately to a physiological stimulus. 
Scopolamine perfusion did not change glucose levels in either WT or L62 (Fig. 5B).  
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In the absence of ischemia, extracellular lactate concentrations in the brain reflect 
formation by astrocytes which support neuronal function in periods of high neuronal 
demand.44 Increase of ACh during the open field correlates with higher neuronal 
activity shown by lactate increases in both L62 and WT to a similar extent (Fig. 5C). 
Lactate levels in L62 mice were slightly higher in the open field experiment, which 
may be explained by increased firing of the ChIs (Fig. 5C, Bonferroni posttest: *: p < 
0.05 vs L62). Mice did not respond with an increase of lactate during stimulation with 
scopolamine (Fig. 5D), probably because scopolamine blocks cholinergic excitation 
of downstream neurons.  
Conclusion 
In this study we investigated the cholinergic system in the striatum in a mouse model 
of synucleinopathy. L62 mice at 9 months of age displayed a cholinergic phenotype 
which was characterized by strong increases of acetylcholine levels under stimulated 
conditions, i.e. in the open field and during scopolamine perfusion. Direct effects of 
synuclein on ChI are possibly due to the co-localization of h-α-syn and ChAT in 
striatal cholinergic interneurons. However, the presynaptic function of cholinergic 
interneurons does not seem to be affected by α-syn, as ChAT, HACU and AChE 
activities are not reduced. In fact, although ChAT positive cells were reduced in the 
striatum, the total activity of ChAT was unchanged and HACU showed an increased 
activity, evidently to maintain the cholinergic function of the synapses. Glucose and 
lactate responded normally, but the higher concentrations of lactate in L62 seen 
during locomotor activity are in agreement with a greater neuronal activity during 
exploration, which is proposed to be due to a disinhibition of cholinergic interneurons.  
Methods 
Chemicals. Neostigmine bromide, scopolamine and chemicals for the artificial 
cerebrospinal fluid (aCSF) were purchased from Sigma-Aldrich (Munich, Germany). 
The chemicals for the mobile phase of the HPLC analysis were obtained from Merck, 
Darmstadt, Germany (KHCO3), from VWR, Darmstadt, Germany (EDTA-2Na), from 
Alfa Aesar, Karlsruhe, Germany (sodium decane-1-sulfonate) and from Sigma-
Aldrich, Munich, Germany (RotisolV HPLC grade water). Chemicals for AChE, ChAT 
and HACU assays were purchased from Biotrend, Köln, Germany ([3H]-choline, [3H]-
acetyl coenzyme A), Sigma-Aldrich, Munich, Germany (acetylthiocholine iodide, 
dithionitrobenzoic acid, Triton X-100, tetraisopropyl pyrophosphoramide, 
hemicholinium-3 and sodium tetraphenylboron) and from Merck, Darmstadt, 
Germany (HEPES sodium salt). CMA 600 Microdialysis analyser reagents (Glucose, 
Lactate and Calibrator reagents) were obtained from M Dialysis AB, Stockholm, 
Sweden.  
Animals. Transgenic mice were generated by GenOway (Lyon, France). Mice were 
previously described and characterized by Frahm et al.16 They were bred in the 
University facility of Charite Berlin and shipped by truck to the animal house in 
Frankfurt. After delivery of the mice they were habituated to the animal facilities for at 
least two weeks. Male and female homozygous L62 mice and WT litters were housed 
in small colonies in a facility with controlled temperature and humidity and a day/night 
cycle of 12/12 h. They had free access to food and water. All experiments were done 
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according to the German Law for Animal Protection (Tierschutzgesetz) and the 
European Community Directive 63/2010/EU. 
ChAT-h-α-syn double labeling and ChI counting. Formalin-fixed brain tissue was 
embedded in paraffin, cut into 5-µm coronal sections, deparaffinised and boiled in 
10mM citric buffer. 
For immunofluorescence, sections were blocked for 1 h in incubation buffer ((5% v/v) 
normal goat serum in PBS containing 0.3% (v/v) Triton X-100) and incubated 
overnight at 4° C in a primary antibody cocktail of mAb 204 (Santa Cruz 
Biotechnology USA, diluted 1:200) and ChAT (H-95, Santa Cruz Biotechnology USA, 
diluted 1:200), diluted in incubation buffer. The next day sections were incubated for 
1.5 h with fluorochrome-conjugated secondary antibodies (Alexa Fluor® 488-
conjugated donkey anti-mouse IgG and Alexa Fluor® 568-conjugated goat anti-rabbit 
IgG, Life Technologies, USA; both diluted 1:500 in incubation buffer) and examined 
using a microscope equipped for fluorescence (Carl Zeiss, Germany). 
For immunohistochemistry, sections were incubated in 0.3% (v/v) hydrogen 
peroxidase solution and blocked for 20 min in blocking buffer (0.1% w/v BSA in PBS). 
Afterwards, ChAT antibody (H-95, diluted 1:50) was added, followed by incubation 
with corresponding biotinylated secondary antibody diluted 1:100 (Dako, Denmark). 
Sections were developed with diaminobenzidine solution (Dako, Denmark), 
counterstained with Ehrlich haematoxylin solution (Carl Roth, Germany), embedded 
in Neo-Mount® (Merck Millipore, Germany) and images taken using a light 
microscope (Carl Zeiss, Jena, Germany). Primary and secondary antibodies were 
diluted in blocking buffer. Cholinergic interneurons were counted manually for the 
entire striatum at Bregma +0.74 ± 0.25 mm (according to Franklin and Paxinos)45 for 
3 consecutive brain sections. The mean value for each animal was used for 
analyses. 
Activity of cholinergic enzymes and transporters. Brain hemispheres were 
homogenized with a 10-fold volume of isotonic HEPES-sucrose buffer (HEPES 
sodium salt 10 mM, Sucrose 0.32 M, pH 7.4) using a tissue grinder (Potter S, B. 
Braun, Melsungen, Germany) at 800 rpm and 15 strokes.  
ChAT was measured by a modification of the Fonnum method.46 Brain homogenate 
containing 0.5 mg/ml protein was added to a total volume of 250 µl reaction mix 
(0.5% Triton X-100, 0.3 M NaCl, 0.02 M EDTA, 0.05 M Na3PO4 pH 7.4, 2 mM choline 
chloride, 1 mM neostigmine bromide, 0.5 mCi [3H]-acetyl coenzyme A). Following 
incubation at 37°C for 15 min, the reaction was stopped by addition of 250 µl ice-cold 
phosphate buffer (1 mM, pH 7.4). ACh was extracted with 1 ml 0.5 % sodium 
tetraphenylboron in 85% toluene-15% acetonitrile. After centrifugation, aliquots of 0.8 
ml were used for tritium quantification with a scintillation counter (Wallac system 
1409, Perkin Elmer). ChAT activity was expressed as nmol of ACh formed per hour 
per mg of protein (nmol/h/mg). Blank values were obtained by omitting the brain 
homogenate.  
HACU activity was determined in synaptosomal (P2) fractions obtained from one 
hemisphere as previously described.47 Brain hemispheres were homogenized in 10 
mM HEPES-sucrose solution and centrifuged at 1,000 g for 10 min at 4°C and, the 
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resulting supernatant centrifuged again at 17,000 g for 10 min. The pellets from the 
last centrifugation step (P2 fraction, containing the synaptosomes) were used for 
HACU determination. Aliquots were incubated at 30°C in the presence of 0.5 µM 
[3H]-choline (diluted to 0.5 Ci/mmol; Biotrend, Cologne, Germany) in Krebs-Henseleit 
buffer (KHB; containing NaCl 115 mM, KCl 7.1 mM, CaCl2 1.2 mM, MgSO4 1.2 mM, 
NaHCO3 25 mM, Na2HPO4 1.5 mM, glucose 12.8 mM, and saturated with carbogen 
adjusting to pH 7.2-7.4). Incubations were done both, in the presence and absence of 
1 µM hemicholinium-3 (HC-3). Choline uptake was stopped after 5 min by placing the 
reaction mix on ice and by adding ice-cold KHB. After three centrifugation steps 
(14,000 g, 10 min) and washing with KHB buffer, the pellets were solubilized in 0.5 ml 
methanol and 4 ml scintillation fluid (IRGA-SAFE PLUS, Perkin Elmer) and used for 
tritium quantification by liquid scintillation counting. The HC-3-sensitive, high-affinity 
choline uptake was calculated as the difference between uptake in the absence and 
presence of HC-3 and expressed as dpm/mg protein. Protein content was 
determined by the Bradford method.  
AChE activity was measured by a modified Ellman method.48,49 Brain homogenate 
(50 µl) was mixed with 0.5% Triton X-100 (Sigma-Aldrich, Munich, Germany) to 
dissolve membranes. Samples were centrifuged for 10 min. at 12,000 g and 4°C. 10 
µl of the supernatant was mixed with Ellman buffer and iso-OMPA (final 
concentration 100 µM). Acetylthiocholine and dithionitrobenzoic acid (1 mM and 500 
µM final concentrations, respectively) were added before measuring the absorbance 
at 405 nm using a Victor multi-label plate reader (Perkin Elmer, Bedford, USA). 
Enzyme activity was calculated using a standard curve prepared with each assay and 
expressed in relation to protein amount (mU/mg protein). Protein determination was 
carried out using the Bradford method.50 
Probe implantation. Self-made, I-shaped, concentric dialysis probes with an 
exchange length of 2 mm and a molecular cut-off of 10,000 Da were constructed as 
previously described.51 The in vitro recovery of the self-built probes amounted to 18.5 
± 2.7 % for ACh and 23.2 ± 2.8 % for Ch. After at least one week of acclimatization to 
the housing conditions, the microdialysis probes were implanted. Mice were 
anaesthetized with isoflurane (Forene®, Abbvie, Ludwigshafen, Germany) in 
concentrations (v/v) of 4% isoflurane in air for induction and 1.5-2% isoflurane for 
maintenance of anesthesia by a vaporisator (Kent Scientific, USA). The skull was 
exposed and a small hole was drilled in the skull of one hemisphere. By means of a 
stereotaxic apparatus (Stoelting, Chicago, USA), the probes were implanted into the 
dorsal striatum using the following coordinates from bregma: AP: +0.5 mm, L: +2.2 
mm, DV: -2.3 mm, according to the atlas of Franklin and Paxinos.45 Glass ionomer 
eluting cement (Micron® i-Cem, PrevestDenPro, Heidelberg, Germany) was used to 
fix the implanted probe on the skull. All animals were allowed to recover at least 18 
hours after surgery before starting the microdialysis experiments.  
In vivo microdialysis procedures. Microdialysis experiments were carried out for 
two consecutive days after probe implantation. Artificial cerebrospinal fluid (aCSF; 
147 mM NaCl, 4 mM KCl, 1.2 mM CaCl2, 1.2 mM MgCl2) was pumped through the 
probe at a constant rate of 2 µl/min with a microinjection pump. Dialysate samples 
(20 µl) were collected every 10 min and immediately stored on ice. After collection, 
samples were frozen at -80°C until analysis. For detection of extracellular ACh, 
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neostigmine (0.1 µM) was added to the perfusion liquid to stabilize basal extracellular 
ACh levels for the following stimulating experiments. On day one of microdialysis, 
after collection of basal levels for 60 min, mice were placed in a novel environment 
(open field box, 35x32x20 cm) for 90 min to physiologically stimulate the ACh release 
due to exploration and increased locomotor activity. After the open field stimulation, 
mice were placed back into their home cage and dialysis was continued for another 
90 min. On day two, baseline levels were collected for 60 min and then scopolamine 
(1 µM) was infused for 90 min through the microdialysis probe to increase ACh 
release pharmacologically. After stimulation, dialysis was continued without 
scopolamine for another 90 min. Subsequently, mice were sacrificed and brains were 
sectioned to verify the correct location of the probe in the dorsal striatum. The 
hemisphere without probe implantation was used to prepare homogenates (see 
above) for the measurement of acetylcholinesterase (AChE) activity, choline 
acetyltransferase (ChAT) activity and high-affinity choline uptake (HACU).  
Determination of Acetylcholine, Choline, Glucose and Lactate. ACh and choline 
(Ch) were analyzed by directly injecting dialysates into a high performance liquid 
chromatography (HPLC) system (Eicom HTEC-500, Kyoto, Japan) consisting of 
degasser, low-speed pump, pre- and separation column, enzyme reactor carrying 
immobilized AChE and choline oxidase, and an electrochemical detector with a 
platinum electrode operating at 500 mV relative to an Ag/AgCl reference electrode. 
The mobile phase contained 50 mM KHCO3, 134 µM Na2EDTA, and 1.6 mM sodium 
decane-1-sulfonate dissolved in RotisolV® HPLC gradient water (pH 8.4). The flow 
rate was set to 150 µl/min and the injection volume was 10 µl. In this condition the 
sensitivity of the assay for ACh is about 1-3 fmol per sample. Data acquisition was 
performed using EPC-500 PowerChrom® software. After detection of ACh and Ch, 
the dialysates were analyzed in the CMA-600 microdialysis analyser (CMA 
Microdialysis AB, Stockholm, Sweden) to determine the concentrations of glucose 
and lactate by an enzymatic reaction and colorimetric detection at 530 nm.  
Data analysis and statistical evaluation. Data for the in vitro recovery of 
microdialysis probes were given as means ± standard deviation (SD). Concentrations 
of ACh, Ch, energy metabolites and enzyme activities were expressed as means ± 
standard error of the mean (SEM) for the respective group with the number of 
experiments indicated in figure legends. AChE and ChAT activity was analyzed with 
Student’s t-test using Prism 5 (GraphPad® Software, San Diego, USA). Two-way 
ANOVA and Bonferroni post-test was used to analyze baseline concentrations of 
ACh, Ch and manual ChI counting (with age and genotype as variables) and for 
glucose and lactate levels (with challenge and genotype as variables). ACh and Ch 
time courses as obtained by microdialysis were also analyzed using two-way ANOVA 
for repeated measures (time and genotype as variables) and Bonferroni post-test. 
Significance of data was assumed when statements could be made with 95% 
confidence.  
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